Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL

platelet count
lenalidomide
revlimid
neutrophil count
lymphoid leukemia
  • 42 views
  • 07 Nov, 2020
  • 3 locations
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal …

lymphoma
treatment regimen
bexarotene
extracorporeal photopheresis
mycosis
  • 112 views
  • 08 Nov, 2020
  • 1 location
Study of SubQ Dara With Dose-Attenuated Bortezomib Lenalidomide Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 28 Jan, 2021
  • 1 location
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

To characterize safety associated with the use of Kyprolis under the locally approved label.

  • 0 views
  • 27 Jan, 2021
  • 10 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

measurable disease
cell transplantation
high dose chemotherapy
lenalidomide
chemotherapy regimen
  • 14 views
  • 15 Apr, 2021
  • 31 locations
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

The study drug elotuzumab, has been clinically shown to be effective in treating relapsed/refractory MM in combination with either bortezomib, or lenalidomide and dexamethasone. Elotuzumab in combination with lenalidomide and dexamethasone is currently approved by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma. Carfilzomib …

measurable disease
line of therapy
elotuzumab
dexamethasone
ejection fraction
  • 3 views
  • 01 Feb, 2021
  • 2 locations
Venetoclax Ibrutinib Prednisone Obinutuzumab and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Background B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective To study …

ibrutinib
diffuse large b-cell lymphoma
granulocyte colony stimulating factor
venetoclax
flow cytometry
  • 69 views
  • 29 Apr, 2021
  • 1 location
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

measurable disease
daratumumab
therapeutic regimen
immunoglobulins
ibrutinib
  • 2 views
  • 28 Mar, 2021
  • 5 locations
Carfilzomib Lenalidomide and Dexamethasone Versus Bortezomib Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly

measurable disease
serum proteins
immunoglobulins
electrophoresis
revlimid
  • 71 views
  • 24 Jan, 2021
  • 1 location
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

A PET-CT will be performed on patients with myeloma after a standard first-line treatment. The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd), before a new

carfilzomib
lenalidomide
dexamethasone
revlimid
neutrophil count
  • 2 views
  • 11 Mar, 2021
  • 4 locations